Ridge Bio
Ridge Biotechnologies builds precision enzymes and targeted drug components to enable more selective therapeutic delivery and activation. The company uses proprietary machine learning models trained on large cell-free, high-throughput datasets combined with experimental enzyme engineering to design bioconjugation enzymes, conditionally activatable linkers, and catalytic biologics. Product lines include NativeLink enzymes for precision bioconjugation, ProTrigger linkers for tissue- and disease-specific payload release, and emerging classes of Catalytic Medicines for therapeutic catalysis. Ridge operates as a B2B biotech platform working with pharmaceutical and biotech partners across applications such as ADCs, antibody-oligonucleotide conjugates, prodrugs, in vivo CAR-T, targeted nucleic acid delivery, and radiotherapy.
Ridge Bio
Ridge Biotechnologies builds precision enzymes and targeted drug components to enable more selective therapeutic delivery and activation. The company uses proprietary machine learning models trained on large cell-free, high-throughput datasets combined with experimental enzyme engineering to design bioconjugation enzymes, conditionally activatable linkers, and catalytic biologics. Product lines include NativeLink enzymes for precision bioconjugation, ProTrigger linkers for tissue- and disease-specific payload release, and emerging classes of Catalytic Medicines for therapeutic catalysis. Ridge operates as a B2B biotech platform working with pharmaceutical and biotech partners across applications such as ADCs, antibody-oligonucleotide conjugates, prodrugs, in vivo CAR-T, targeted nucleic acid delivery, and radiotherapy.